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ABSTRACT This article provides an overview of outstanding sessions that were (co)organised by the Allied
Respiratory Professionals Assembly during the European Respiratory Society International Congress 2020,
which this year assumed a virtual format. The content of the sessions was mainly targeted at allied
respiratory professionals, including respiratory function technologists and scientists, physiotherapists, and
nurses. Short take-home messages related to spirometry and exercise testing are provided, highlighting the
importance of quality control. The need for quality improvement in sleep interventions is underlined as it
may enhance patient outcomes and the working capacity of healthcare services. The promising role of digital
health in chronic disease management is discussed, with emphasis on the value of end-user participation in
the development of these technologies. Evidence on the effectiveness of airway clearance techniques in
chronic respiratory conditions is provided along with the rationale for its use and challenges to be addressed
in future research. The importance of assessing, preventing and reversing frailty in respiratory patients is
discussed, with a clear focus on exercise-based interventions. Research on the impact of disease-specific fear
and anxiety on patient outcomes draws attention to the need for early assessment and intervention. Finally,
advances in nursing care related to treatment adherence, self-management and patients’ perspectives in
asthma and chronic obstructive pulmonary disease are provided, highlighting the need for patient
engagement and shared decision making. This highlights article provides readers with valuable insight into
the latest scientific data and emerging areas affecting clinical practice of allied respiratory professionals.
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The virtual European Respiratory Society (ERS) International Congress 2020 offered allied respiratory
professionals a wide range of appealing sessions (co)organised by Assembly 9 (Allied Respiratory
Professionals), including symposia, Expert View, Hot Topics, Clinical Year in Review and 266 abstract
sessions spread over four oral communication and 13 e-poster sessions.
Early Career Members of the Allied Respiratory Professionals Assembly, including respiratory function
technologists and scientists (E. Smith and M. Thomas), physiotherapists (E. Calik-Kutukcu and
I. Torres-Sánchez), and nurses (M. Granados-Santiago and J.C. Quijano-Campos), were invited to report
on the following sessions selected by group chairs of the Assembly, which focused on recent research
advances: two oral presentation sessions on the quality improvements in lung function and sleep
diagnostics, and novel insights into nursing interventions for managing patients with asthma and chronic
obstructive pulmonary disease (COPD); three symposia on digital health, managing frailty in patients with
acute or chronic lung disorders and psychological wellbeing in chronic lung diseases; and an Expert View
in physiotherapy in chronic respiratory infections with a focus on airway clearance techniques. We
summarised the latest scientific and clinical insights gained from each session, targeting delegates who
were present in the virtual sessions as well as those unable to attend.
Group 9.01: Respiratory Function Technologists and Scientists
Oral presentation session: Quality improvements in lung function and sleep diagnostics
This oral presentation session included the highest scored abstracts submitted to the Respiratory Function
Technologists and Scientists (9.01) group.
Quality improvements in a sleep clinic: to increase capacity and time to treat in patients with
obstructive sleep apnoea (P. Coss, Ireland)
P. Coss described the outcome of a quality improvement programme in the Sleep Dept at St James’s
Hospital (Dublin, Ireland). This sought to reduce the time to treatment from a pre-intervention of
32 weeks to 9 weeks and address inefficiencies to increase the capacity of the department. Pareto analysis
showed that the most significant delay was caused by general practitioner referral to the first appointment
with the sleep consultant. Through a series of Plan–Do–Study–Act (PDSA) cycles, the team identified
those interventions which added value, which included adopting a Proforma for assessing the sleepy
patient, and co-locating consultant and physiologist assessments. Following the interventions, attendance
was shown to be both improved and more consistent. The time from initial intervention to review in the
sleep clinic was reduced from 196 to 14 days and the number of new patients seen per month increased
from four to 15. This talk was an excellent example of how standard quality improvement processes can
be implemented in routine practice to achieve significant patient benefits.
Early effect of continuous positive airway pressure therapy on right ventricular function in patients
with newly diagnosed obstructive sleep apnoea (P. Coss, Ireland)
The second of piece of work presented by P. Coss was part of a cross-departmental project built on
previous findings [1] and analysed right ventricular function in 19 obstructive sleep apnoea (OSA) patients
(70% male) following a 12-week intervention of continuous positive airway pressure (CPAP) treatment
(mean compliance 4.1 h·night−1). Outcome measures included basal right ventricular diameter, tricuspid
annular plane systolic excursion (TAPSE) and fractional area change (FAC), the latter two being measures
of global right ventricular function. Following CPAP treatment, a small but significant reduction in right
ventricular size, and an increase in FAC and TAPSE, i.e. markers of improved right ventricular ejection,
was observed. It was proposed that, in patients with OSA, there are likely subclinical changes in the
structure and function of the heart which are, at least in part, reversible with the application of CPAP
treatment. The presented results are preliminary and it will be exciting to see the results of the study once
completed.
Quality control of cardiopulmonary exercise equipment (T. Souren, Belgium)
T. Souren presented an observation of the performance of four metabolic carts in use at University
Hospital Antwerp (Antwerp, Belgium). The team used the Metabolic Simulator (Relitech Systems, Nijkerk,
The Netherlands) to verify the performance of each cart at four different metabolic levels, with breathing
frequencies from 20 to 80 breaths·min−1, and oxygen uptake (V′O2) and carbon dioxide production (V′CO2)
from 1 to 4 L·min−1. The carts studied included the Metalyser II (Cortex, Leipzig, Germany), Powercube
(Ganshorn, Niederlauer, Germany), CPET Oxygen Sensor II (Geratherm Respiratory, Bad Kissingen,
Germany) and Vyntus CPX (Vyaire, Mettawa, IL, USA). Varying performance of the four devices was
demonstrated, with all devices being outside of the acceptability limits at least once (3% for V′O2 and
V′CO2, 2% for minute ventilation (V′E), and 0.04 absolute for respiratory exchange ratio (RER)). It is
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advocated that a metabolic simulator should be part of at least a once-yearly routine quality check of
metabolic carts and used as a complementary practice to the use of biological controls, to understand
equipment variability and impacts on future data collection.
A RER of 1.05 should not be used to determine maximal effort during cardiopulmonary exercise
testing (M. Thomas, UK)
M. Thomas presented a review of the American Thoracic Society (ATS)/American College of Chest
Physicians [2] and ERS [3] recommendations for determining maximal effort during cardiopulmonary
exercise testing (CPET) and noted that both publications quoted target RER values (>1.15 and >1.05,
respectively). A retrospective review of CPET data collected at University Hospital Birmingham
(Birmingham, UK), where the patient achieved an RER >1.15 (n=176) to determine CPET outcomes at
RERs of 1.05 and 1.15, compared with volitional exhaustion, was performed. From the patients assessed
for pre-operative risk, at volitional exhaustion, 25% were classified as high risk (V′O2 <15 mL·min·kg
−1),
whereas at RER=1.05 and RER=1.15, 77% and 45% of patients were considered high risk, respectively. In a
subanalysis of patients investigated for unknown cause of breathlessness, the proportion of those who
returned an abnormal result based on ERS criteria [3] was 63%, 75% and 97% at volitional exhaustion,
RER=1.15 and RER=1.05, respectively. The team provided robust evidence that a pre-determined RER
value should not be used to determine the end of test as this is likely to overestimate pre-operative risk
and result in mismanagement of patients undergoing CPET for diagnostic purposes.
A comparison of three sets of paediatric reference values for CPET using cycle ergometry
(P. Burns, UK)
P. Burns from the Royal Hospital for Children (Glasgow, UK) presented percent predicted V′O2 peak
(n=766), where predicted values were calculated using three commonly used reference equations from
COOPER et al. [4], BLANCHARD et al. [5] and BONGERS et al. [6]. Bland–Altman analysis demonstrated wide
limits of agreement (LoA) between all three equations, which was the greatest for Cooper versus Bongers
(upper LoA 48%, lower LoA −26%). It was noted that the commonly used Cooper equation was derived
from the smallest dataset (n=109) and simplest data analysis but the largest age range (6–17 years), and
while the Blanchard equation looks initially promising with the largest dataset and multivariate analysis, it
was limited in its use in a paediatric laboratory due to the age range of subjects included (12–18 years).
Findings evidenced that the reference equation used will have pronounced implications on the
interpretation of paediatric CPET data, and that a “Global Lung Function Initiative” (GLI) approach of all
age reference equations for CPET is needed to standardise laboratory practice and advance the field.
Deep learning automates complete quality control of spirometric manoeuvres (N. Das, Belgium)
N. Das, a PhD candidate from Leuven University (Leuven, Belgium), presented one study on the use of
deep learning for the purpose of spirometry quality control. The model presented was built upon previous
work [7], further including the criteria of tidal breathing and maximal inspiration before and after forced
expiration. Using the sample dataset, the convolutional neural network model had a greater area under the
receiver operating characteristic curve (0.91), accuracy (87%) and specificity (81%) than the technician
ATS/ERS rule-based model (0.77, 67% and 32%, respectively) [8]. The major strength identified, aside
from the accuracy, was that the Shapley values were able to provide a clear visual feedback as to why the
manoeuvre had failed the quality control check.
This was an excellent example of how deep learning could be used to complement the visual cognition of
skilled technicians, working towards the automatic definition of spirometric acceptability. The authors of
the study are currently looking to adapt the tool to accommodate the latest 2019 guidelines [9].
Differences between percent predicted and z-score: the impact of severity classification in
spirometry (A. Silva, Portugal)
The final presentation in this session, from A. Silva, highlighted that the severity criteria used can affect
the classification of disease in a paediatric population. The 2012 GLI reference equations [10] were used to
generate percent predicted and z-scores for 1869 children (aged 3–18 years, 55% male) who attended Santa
Maria Hospital (Lisbon, Portugal). Normality and severity classifications were defined according to both
the 2005 ATS/ERS criteria [11] and the more recent 2014 proposal by QUANJER et al. [12] (table 1). 19% of
the spirometry tests returned a different severity classification using the two methods described. Using
QUANJER et al. [12] criteria, 27% (120 out of 440) of mild (ATS/ERS) cases were classified as normal.
Notably, almost all ATS/ERS definitions of moderate (77 out of 84), moderate to severe (44 out of 44) and
severe (39 out of 41) cases increased by ∼1 severity score when reanalysed using Quanjer’s z-score model.
While it was agreed that the new classification system is simple and easy to implement, it was also
acknowledged that this would affect severity classification in some children which requires clinical
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validation. It should, however, be noted that clinical validation of the ATS/ERS severity scoring system is
not yet robust.
Take-home messages
• There exist multiple tools for interpreting respiratory function data, the choice of which can have profound
implications for disease classification. This requires further standardisation across the field.
• Internal quality improvement plans can be effective tools to increase the capacity and efficiency of a sleep
department.
• CPET should not be terminated at a pre-determined RER but performed to volitional exhaustion, when it
is safe to do so.
• A metabolic simulator can be a valuable tool to understand inherent differences between metabolic carts,
when used as an adjunct to a biological control programme.
• The automation of spirometry quality control is being advanced by machine learning.
Symposium: Digital health: a brave new world?
The healthcare sector is being rapidly transformed by the development and innovation of digital
technologies. This symposium started by focusing on patients and end-users of these technologies, before
focusing on specific applications of digital technologies in the management of asthma; it ended by looking
at new horizons in digital technologies in respiratory medicine and discussing the promise of artificial
intelligence.
The patient’s perspective (D. Hamerlijnck, The Netherlands)
D. Hamerlijnck is a patient expert with severe asthma. In this presentation, D. Hamerlijnck postulated that
the vision for the future digitisation of care seemed to be replacing the doctor with an algorithm based on
guidelines [13]. While this is a useful strategy for the majority of patients, these guidelines are based on
what is most common in a patient population. D. Hamerlijnck reported to be an example in which these
algorithms cause issues, because D. Hamerlijnck is a patient with severe asthma who does not wheeze or
cough. The talk then focused on patient advocacy and ensuring that patients and end-users are involved in
the development of these digital technologies. The other speakers in this session all dedicated time in their
presentations to reinforce the message that patient and end-user involvement is crucial to the future of
these technologies.
Digital technology for asthma (O.S. Usmani, UK)
This presentation addressed the use of digital technologies in the management and diagnosis of asthma.
O.S. Usmani suggested the key drivers for digital solutions are prevalence of disease, advancements in
technology (both innovation of technology and patient digital literacy) and patient engagement.
Development of digital technologies is critical in asthma with 300 million patients worldwide, 50% of
which do not take medications as prescribed and 60% do not attend follow-ups [14]. Initial focus in the
development of these technologies in asthma was on monitoring medication remotely. The aim was to
identify those patients poorly controlled and in need of additional attention to help achieve disease
control. Innovations employed included digital inhaler trackers [15] and new methods of monitoring
device adherence [16]. SULAIMAN et al. [17] developed an electronic acoustic recording device for dry
powder inhalers to identify the types of error with their use. They found that 48% of patients would fail to
generate a peak inspiratory flow rate >35 L·min−1. Other errors identified included patients performing
multiple inhalations (23%), not inhaling at all despite introducing the blister pack (7.4%) or exhaling into
TABLE 1 Recommendations for the classification of airway obstruction severity, as defined by
the 2005 American Thoracic Society/European Respiratory Society guidelines [11] (% pred) and
the more recent 2014 proposal by QUANJER et al. [12] (z-score)




Moderate to severe 50–59 −3.0–−2.5
Severe 35–49 −4.0–−3.0
Very severe <35 <−4.0
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the device (5.4%). Smart sensors introduced in inhaler devices demonstrated higher adherence in children
aged 6–15 years compared with the same device with the sensor function disabled (84% versus 30%) [18].
The use of mobile applications for self-management of asthma was systematically reviewed by HUI et al. [19].
The most successful interventions included multiple features such as symptom monitoring and medication
reminders. O.S. Usmani then echoed D. Hamerlijnck’s message about the importance of including the
patient and end-users in the digital technology development process, and detailed a project called
“myaircoach” that involves the analysis, modelling and sensing of both physiological and environmental
factors for the customised and predictive self-management of asthma. The group developing the project is
making the user the centre of its design and implementation by approaching asthma patients and healthcare
practitioners regarding the functionality and use of these systems for self-management [20]. Patients were
most interested in technology improving self-monitoring, collecting data to present to healthcare
professionals that demonstrates how their asthma has been, and alerting the patients and/or healthcare
professionals to a deterioration in their asthma control before they would normally notice. In contrast,
healthcare professionals wanted a device that offers advice regarding when additional medical attention
should be sought or that provides instructions on how to manage their asthma in an emergency.
Artificial intelligence in respiratory medicine (V. Poberezhets, Ukraine)
V. Poberezhets discussed new horizons in digital technologies for respiratory medicine where an
ontological structure of digital medicine was presented (figure 1) [21]. The use of artificial intelligence
(AI) and machine learning has been employed to improve diagnostic yield and decrease workload in
thoracic imaging [22, 23], histopathology and cytology [24, 25]. AI could be used to improve diagnostic
accuracy in the interpretation of pulmonary function tests, where it was demonstrated to have a higher
degree of accuracy than pulmonologists [26].
V. Poberezhets highlighted interesting future developments in AI such as clinical decision support systems
that will aggregate all data obtained in a patient’s pathway [27]. The current systems are limited by having
to process unstructured data such as patient complaints or observations made in clinical examinations and
recorded in notes; AI may address these issues.
Artificial intelligence in clinical trials (K. Kostikas, Greece)
K. Kostikas’s talk detailed the promise of AI in clinical trials and research. The traditional drug
development cycle takes up to 15 years and requires up to EUR1.7 billion, and AI may be able to reduce
these figures by aiding in clinical trial design, feasibility assessment, patient recruitment, blinding of trials
by aggregating anonymous data, performing the literature review, matching patients, real-time monitoring
of data during trials, data collection and sharing [28]. AI has theoretical applications to increase study
power by reducing population heterogeneity, for prognostic enrichment by selecting patients more likely to
have measurable clinical end-points and for predictive enrichment by identifying patients more likely to
































FIGURE 1 The ontological structure of digital medicine. Reproduced from [21] with permission.
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Take-home messages
• Patient’s trust in clinicians is, in part, developed by nonverbal communications that can be impaired by
remote technologies and tele-consultations. Future technologies should consider this during
development.
• The end-users are both patients and clinicians, and both have distinctly different desires and expectations
for remote monitoring tools.
• AI is not being developed to replace clinicians and we should embrace it, not fear it: “a computer is not
better than a human brain, but a computer supporting the human brain is better than the human brain
alone”.
Group 9.02: Physiotherapists
Expert View: Physiotherapy in chronic respiratory infections (A. Spinou, UK)
According to the PICO (Population, Intervention, Comparison, Outcome) framework [30], A. Spinou
presented a detailed overview about the ability of airway clearance techniques to reduce the rate of
exacerbations, hospitalisations or improve quality of life in patients with COPD, cystic fibrosis (CF) and
bronchiectasis. First, A. Spinou gave some background information about airway clearance techniques and
presented airway clearance technique evidence for these three chronic respiratory diseases. A. Spinou then
talked about research challenges in this area and the implementation of airway clearance techniques in
clinical practice.
Airway clearance is a defence mechanism that is based on the relationship between the mucociliary
escalator and cough. Cough is important for effective clearance of secretions in addition to helping to
collect thicker secretions and increase secretion volume. Another important factor for removing secretions
is airway surface liquid [31]. Airway clearance is compromised in some diseases due to impaired
mucociliary function, alterations in secretion production and mucus rheology (i.e. fluid flow and
deformation for mucus), and impaired cough reflex as a defence mechanism [32]. The main problem is
that patients with bronchiectasis enter a vicious cycle in which impaired mucociliary clearance leads to
structural airway damage and consequently lower airway tract infection that leads to inflammation.
Inflammation causes recurrent pulmonary infections that increase mucus production. Airway clearance
techniques have the potential to break this cycle as increasing mucociliary clearance decreases structural
airway damage [33]. Airway clearance techniques are techniques (with or without the use of devices) that
have been employed alone and in combination to facilitate airway clearance and increase the effectiveness
of cough. Techniques include gravity-assisted positioning/postural drainage, manual techniques like
percussion, vibrations, shaking and overpressure, active cycle of breathing techniques (ACBT), autogenic
drainage and slow expiration with the glottis opened in the lateral posture (ELTGOL). There are also many
devices to assist airway clearance: positive expiratory pressure (PEP), oscillating PEP and high-frequency
chest wall oscillation devices [34]. The rationale of these techniques and devices is based on physiological
mechanisms including gravity/positioning, mucous viscoelasticity, two-phase gas–liquid interaction,
collateral ventilation, interdependence and equal pressure point [35]. Interestingly, some techniques are
most preferred in different countries; whereas ACBT is the most preferred method in the UK, PEP devices
are frequently used in the USA by physiotherapists treating patients with bronchiectasis [36].
The outcomes most frequently used to assess the effectiveness of airway clearance techniques are sputum
volume/weight (dry or wet), mucus transport rate, ventilation scanning, pulmonary function, lung
clearance index, oxygen saturation, symptoms like dyspnoea and cough, adverse effects, duration and
frequency of exacerbations and hospitalisations, need for antibiotics, health-related quality of life, patient
preference, treatment adherence, and mortality [37]. There are few studies that investigate the long-term
effect of airway clearance techniques on outcomes. A Cochrane review comparing airway clearance
techniques to no airway clearance techniques during an acute exacerbation of COPD reported no change
in the number of exacerbations at 6-month follow-up, but it included studies with a small sample size
[38]. In patients with stable COPD, there was a reduction in the need for hospital admission but there was
no change in the total number of days at the hospital in the long term. Studies showed that airway
clearance techniques reduced the need for antibiotics in stable COPD [38]. A multicentre randomised
controlled study also showed that the PEP technique was not effective in reducing the number of
exacerbations, number of respiratory-related hospitalisations, total number of hospitalised days, need for
antibiotics and mortality compared with controls at 6 months of follow-up after an acute exacerbation
[39]. This study also demonstrated that there was no benefit in terms of quality of life [39]. In patients
with bronchiectasis, a Cochrane review reported an improvement in quality of life but no change in
frequency of exacerbations at 3-month follow-up [40]. In a randomised placebo controlled study published
in 2018, patients with bronchiectasis that used the ELTGOL technique showed an improvement in
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cough-related quality of life and health-related quality of life and decreased frequency of exacerbations
[41]. Several Cochrane reviews have been published regarding airway clearance techniques in CF [33, 41].
Most of them compare the effect of different techniques on mortality. A Cochrane review that included
eight studies comparing airway clearance techniques with no airway clearance techniques in CF showed
that no data is available regarding number of exacerbations per year, number of days in hospital per year,
number of days of intravenous antibiotics per year and death [42].
In conclusion, there was low quality of evidence about the effectiveness of airway clearance techniques in
chronic respiratory diseases [43]. The most prevalent methodological issues were difficulties in adherence
and compliance in long-term investigations, ethical problems, lack of blinding, poor study design, poorly
defined or misinterpreted techniques and lack of selecting appropriate outcome measurements. In a
clinical setting, the selection of the optimal airway clearance techniques should take into account the
diagnosis, the severity/stage of disease, whether the patient is in a stable or exacerbation phase and existing
comorbidities. Physiotherapists should also consider underlying physiology, contraindications/precautions,
equipment, cost and burden of treatment technique. Clinicians should also pay attention to preference/
ability, needs, age and treatment adherence of the patients when planning treatment. As a key message,
clinical practice about airway clearance techniques is mainly guided by physiology rationale and
short-term benefits. There is an urgent need to take action and perform high-quality research on the
long-term effectiveness of airway clearance techniques [43].
Take-home messages
• There is low quality of evidence about the effectiveness of airway clearance techniques in chronic
respiratory diseases (COPD, bronchiectasis and CF).
• In a clinical setting, the selection of the optimal airway clearance technique should take into account the
diagnosis, the severity/stage of disease, whether the patient is in a stable or exacerbation phase and
existing comorbidities.
Symposium: Managing frailty in patients with acute or chronic lung disorders
In this symposium, several expert speakers provided an update on the latest knowledge about frailty in
respiratory diseases.
Diagnosing, management and measures of frailty (M. Cesari, Italy)
M. Cesari started by explaining that frailty is not a disease. There is a consensus definition of frailty as “a
medical syndrome with multiple causes and contributors that is characterised by diminished strength,
endurance, and reduced physiologic function that increases an individual’s vulnerability for developing
increased dependency and/or death” [44]. Many practical operational definitions of frailty are available. In
the phenotypic operational definition of frailty provided by FRIED et al. [45], a frail individual was defined
according to a number of predefined criteria: involuntary weight loss, weakness, poor endurance or
exhaustion, slowness and sedentary behaviour. A person is considered frail when meeting at least three
criteria and pre-frail when meeting one or two criteria. Another important school of thought tried to
propose an operational definition that aimed to provide a measure of the age-related accumulation of
deficits that the person presents in order to guess a surrogate of biological ageing [46]. M. Cesari remarked
that the more deficits a person presents, the frailer he/she will be [47].
In the literature, we can find a huge number of instruments available to measure frailty. Nine instruments
are highly cited (over 200 citations). The most common assessment context was observational studies in
older community-dwelling adults [48]. Frailty is the target condition for applying a comprehensive
geriatric assessment [49], a multidimensional diagnostic and therapeutic process for dealing with highly
complex individuals. M. Cesari noted that all information provided can be found in the “Integrated care
for older people” document published by the World Health Organization [50].
Skeletal muscle stem cells and capillaries: important neighbours in muscle tissue of COPD patients
(T. Snijders, The Netherlands)
T. Snijders explained how muscle fibres relate to frailty. Satellite cells, as stem cells, are able to provide
growth and regeneration capabilities to the muscle fibre. Satellite cell content and function are known to
decline with increasing age [51]. Satellite cell function is even lower in COPD patients compared with
age-matched controls and, therefore, it might be a key factor in the accelerated ageing of skeletal muscle
tissue [52]. Circulation plays an important role in the activation and functioning of the satellite cell [53].
Hence, it is not surprising to find satellite cells close to capillaries. This distance has been shown to be
increased in healthy elderly adults compared with young adults (particularly in type II muscle fibres) [54].
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Performing prolonged exercise training can restore the balance between satellite cells and capillaries. The
preliminary results in the studies reported by T. Snijders and co-workers showed no significant difference
in satellite cell content between COPD and age-matched controls. Fibre capillarisation was lower in type I
(and type II) muscle fibres compared with young elders as well as age-matched healthy controls.
Most importantly, T. Snijders and co-workers investigated the satellite cell distance to its nearest capillary
[54]. In healthy young individuals, they found no differences between type I and type II muscle fibres,
while in healthy older adults, this distance was ∼20% higher in type II muscle fibres. In COPD patients,
this distance was equally large in type II muscle fibres compared with healthy older adults. In type I
muscle fibres, there was a greater distance compared with healthy young and healthy older adults. Satellite
cell distance to nearest capillary was greater in type I muscle fibres of COPD versus controls. In
conclusion, changes in muscle tissue are associated with frailty and can be modified by exercise training.
Frailty during and after hospitalisation (M. Herridge, Canada)
M. Herridge spoke about critical illness as a model for frailty, functional and cognitive disability, and the
intersection of these. In the study by BAGSHAW et al. [55], the association between frailty and short- and
long-term outcomes among critically ill patients was shown. They found that frailty was common among
critically ill adults aged ⩾50 years, and identified a population at increased risk of adverse events,
morbidity and mortality. Frailty can be modifiable over time as patients showed that they may transition
to a better frailty state. Disability and cognitive impairment may overlap with frailty, but many patients
acquire frailty in isolation [56].
After a severe episode of acute respiratory distress syndrome (ARDS), patients sustain important muscle
wasting and weakness of ∼20% of their baseline weight [57].
LEVINE et al. [58] and PUTHUCHEARY et al. [59] showed the relentless atrophy of the diaphragm and muscles
of the axial skeleton, respectively. Among older persons with critical illness, more than half died within
1 month or experienced significant functional decline in the following year, with particularly poor
outcomes in those who had high levels of pre-morbid disability. These results may help to inform
discussions about the prognosis and goals of care before and during critical illness [60]. However, it is not
just physical disability but also cognitive disability. HOPKINS et al. [61] showed a decrement in processing
speed, memory, executive function, poor attention and concentration in survivors of severe ARDS. Critical
patients may be vulnerable to long-term cognitive dysfunction [62]. Patients can also show mood
disorders, such as persecutory delusion and post-traumatic stress disorder [63].
Frailty in chronic lung disorders (L. Lahousse, Belgium)
In this presentation, L. Lahousse discussed three main points: 1) the prevalence of frailty in COPD
patients, 2) the mechanisms that frailty and COPD share, and 3) the impact of frailty in patients with
COPD. Frailty is higher in these patients (10.2%) compared with people without COPD (3.4%) and its
prevalence is highly associated with the degree of airflow limitation [64]. The prevalence of pre-frailty is
inversely associated with the severity of airflow limitation. The reason behind this is that people with
severe disease transfer from a pre-frail to a frail state. COPD is closely related to frailty as both are
associated with ageing, smoking, deregulated inflammation and endocrine dysfunction. Mechanisms of
accelerated ageing and related inflammation in genetically susceptible individuals might underlie both
COPD and frailty. Epigenetic alterations and altered intercellular communication are ageing mechanisms
which are likely to be involved in lung diseases such as COPD and idiopathic pulmonary fibrosis (IPF)
[65, 66]. We need to better understand which mechanisms drive frailty in patients with COPD, as frailty
reduces quality of life [67] and increases hospitalisations, hospital readmissions [68] and in-hospital
mortality [69] in these patients.
Rehabilitative interventions to reverse frailty (M. Maddocks, UK)
The final speaker in this symposium discussed rehabilitative interventions in frailty. M. Maddocks
provided an overview of the effectiveness and ease of implementation of a range of possible interventions
regarding frailty. Exercise-based interventions appear to be an overall best solution, comprising both easy
implementation and demonstrated effectiveness [70]. In a study by MADDOCKS et al. [71], results showed
that overall rehabilitation in patients with COPD led to a shift away from frailty and towards a more
robust state. Proportionally, more frail patients experienced deterioration in their condition or hospital
admission during the programme. Frailty was also a strong independent predictor of noncompletion. In
this regard, participants had to overcome unpredictable disruption to participation: some maintained
determination despite disruption, others were supported by rapport and flexibility of services, but for
some, pulmonary rehabilitation was no longer seen as a good fit [72]. A list of approaches on how to
adapt rehabilitation programmes for frailty was given, comprising building trusting relationships, shared
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understanding of priorities, individualised content to match priorities, capacity to address
multidimensional losses and flexibility in service delivery [73].
Take-home messages
• There exist several definitions of frailty and multiple assessment tools to evaluate it.
• Muscle satellite cell content is not significantly different between patients with COPD and healthy
age-matched controls.
• The distance from a muscle satellite cell to its nearest capillaries is significantly greater in patients with
COPD compared with healthy age-matched controls.
• Frailty may be acquired during illness and hospitalisation. It is an independent risk factor for poor
outcome. It may occur with or separate from disability and cognitive impairment. Frailty may be uniquely
amenable to rehabilitation and represent a novel opportunity for intervention.
• Frailty is common (>10%) in patients with COPD and is the strongest determinant of survival in COPD.
Frailty and COPD share inflammatory mechanisms.
• Frailty can be prevented and reversed by rehabilitation. Exercise remains a powerful intervention for
people with respiratory disease and frailty.
• Pulmonary rehabilitation needs to “flex” to ensure a good fit for some of this group, without
compromising quality.
Group 9.03: Nurses
Symposium: Fear and anxiety, psychological wellbeing and prevention of psychological distress in
chronic lung diseases
This symposium aimed to identify psychological symptoms in chronic respiratory patients and provide
novel treatment approaches that focus on psychological wellbeing and prevention of psychological distress.
Four respiratory expert speakers provided an update on the latest knowledge about psychological
comorbidities and its management. In addition, the testimony of a patient with a diagnosis of IPF was
included.
The patient’s perspective (R. Flewett, UK)
This symposium presented the opportunity to voice the experience of a patient with IPF giving advice for
healthcare professionals. R. Flewett was diagnosed with IPF at the age of 53 years and given a life
expectancy of 3–5 years. “I just felt so alone and so desperate at that point, having no one to turn to for
help”, R. Flewett said after diagnosis. Frustrated by previous medical experiences, fears and changing
moods, R. Flewett provided four points of advice to healthcare professionals: 1) encourage communication,
2) reassure the patient that it is OK to feel sad, 3) put them in touch with other chronic patients and
3) promote exercise but clarify the dangers of overexertion. R. Flewett highlighted the nurse–patient
relationship, which enables patients’ requirements to be identified in a confidential environment, and the
perception of the patient’s family, the caregiver mainly. R. Flewett emphasised that “sometimes it is the
simplest gestures that can help to unlock suppressed emotions”.
Disease-specific fears in COPD (T. Rejinders, Belgium)
Anxiety is the main psychological comorbidity, being observed in 10–55% of patients with COPD [74].
Multiple studies have suggested that disease-specific fears of patients with COPD may aid or interfere with
participation in pulmonary rehabilitation and self-care [75, 76]. The principal fears of these patients are
dyspnoea perception and physical activity because of the increase in this symptom [77]. Patients showed a
greater perception, but also greater neural processing of respiratory sensations, which emphasises the
attention-demanding feature of these sensations [78]. Patients with COPD with higher levels of
dyspnoea-specific fear show increased attention to respiratory sensations and decreased physical
activity. T. Rejinders demonstrated that high levels of disease-specific fears independent of general anxiety
were associated with poor outcomes of pulmonary rehabilitation in patients with COPD [79]. Therefore,
dyspnoea-specific fears in patients with COPD should be identified as early as possible to improve the
effects of pulmonary rehabilitation.
Nurse-led cognitive behavioural therapy in COPD (K. Heslop-Marshall, UK)
Dyspnoea is the main symptom in patients with COPD. However, anxiety and depression have a
significant impact despite not being evaluated and treated properly. Thus, the key elements of
self-management in patients with COPD are: 1) mental health, 2) physical activity and 3) addressing
physical symptoms. K. Heslop-Marshall highlighted the importance of addressing psychological
comorbidities and how cognitive behavioural therapy (CBT) delivered by respiratory nurses can help
patients with COPD. CBT is an evidence-based intervention for anxiety and depression in the general
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population [80]. This intervention was found to decrease anxiety levels and reduce resources use and
hospital admission in patients with COPD, being a cost-effective intervention [81].
Expressing empathy in 15 min or less: challenges for clinicians (D. Reynolds-Sandford, Australia)
Empathy is the ability to understand and share the feelings of another person, discovering what that
person needs, and then giving that [82]. Empathy is a skill anyone can develop. Practising empathy
involves: 1) understanding and responding to the suffering of others, 2) challenging prejudices and
preconceived ideas, 3) practising active listening, and 4) speaking up [83]. Healthcare interventions
provided with empathy showed many benefits, including enhanced patient’s experiences, adherence to
treatment recommendations, better clinical outcomes and fewer malpractice claims [84]. Nevertheless,
there is a negative part with a higher psychological cost to healthcare professionals. “Vicarious trauma”
refers to the professional’s continuous emotional engagement with patients’ problems that creates cognitive
distortions and changes in core belief systems within the professionals [85]. It is important that healthcare
professionals understand the symptoms associated with this phenomenon to identify, prevent and/or
minimise their effects.
Integrating early palliative care for patients with IPF and their caregivers (K. Lindell, USA)
IPF is associated with variable disease course, tremendous symptom burden and poor quality of life [86].
Palliative care should be initiated early in the illness course according to the individual patient’s needs,
preferences and culture to overcome the symptom burden and poor quality of life [87]. SUPPORT is an
intervention aimed to provide education about seven key elements in IPF patients: (S) symptom
management, (U) understanding their disease, (P) pulmonary rehabilitation, (P) palliative care, (O) oxygen
therapy, (R) research opportunities and (T) transplantation. The final objectives of SUPPORT were
understanding the illness, caring for the patient, providing information for the carer, and planning for the
future to improve symptom burden and quality of life [88].
Take-home messages
• The main fears of patients with COPD are dyspnoea perception and physical activity.
• CBT is a cost-effective intervention to decrease anxiety levels in patients with COPD.
• Empathy is a skill that healthcare professionals can develop to enhance patients’ experiences and clinical
outcomes.
• Palliative care should be initiated early in the illness course to overcome the symptom burden and poor
quality of life.
Oral presentation: Novel insights into nursing interventions for managing patients with asthma
and COPD
This virtual oral presentation session provided an overview of state-of-the-art advances in nursing care
related to respiratory conditions by focusing on three main themes: treatment adherence (three
presentations), self-management (two presentations) and patients’ perspectives (two presentations).
Treatment adherence
Reasons for inhaled corticosteroid nonadherence disclosed by African American adults during
primary care visits for uncontrolled asthma (M. George, USA)
M. George’s group aimed to identify reasons for inhaled corticosteroid (ICS) nonadherence by African
American adults with asthma during primary care visits. Using grounded theory, three themes emerged
from the analysis of audio recordings of 80 visits for uncontrolled asthma within African American adults:
1) personal misconceptions, 2) management confusions and 3) external influence. Findings suggest that
primary care providers should assess patients’ knowledge, beliefs and suspicions, and consider
patient-centred strategies to improve ICS adherence (e.g. shared decision making and patient engagement).
Treatment adherence among adults with asthma: a report from the OLIN asthma cohort
(S.W. Lindmark, Sweden)
Similarly to the study to M. George, in the study presented by S.W. Lindmark, 1006 adults with asthma
were followed up to study pharmacological treatment adherence in northern Sweden. Results showed that
579 participants used asthma treatment during the last year and also that that three out of five had high
adherence according to the MARS-5 medication adherence report scale. Forgetfulness was the most
common reason for nonadherence and males had poorer adherence than females. The authors of the
study emphasised the importance of healthcare professionals to monitor adherence and reasons for
nonadherence among patients with asthma.
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Study to evaluate satisfaction with the inhalation device used by patients with asthma or COPD
and the association with adherence and disease control (D. Diaz-Perez, Spain)
D. Diaz-Perez presented a multicentre observational cross-sectional study evaluating patients’ satisfaction
with the inhalation device used and its association with adherence and disease control. The study included
400 participants with asthma and COPD, and results showed a high degree of satisfaction, with no
difference among device types [89]. Furthermore, having a higher level of education was associated with a
higher level of satisfaction. Findings suggest that shared decision making between patients and healthcare
professionals is a key factor for the acceptance of the inhalation device.
Self-management
Ecare-COPD: a massive open online course to empower nurses to enhance self-management
skills in patients with COPD (M. Padilha, Portugal)
Ecare-COPD was presented by M. Padilha as an online training programme for nurses to promote
self-management in people with COPD. This e-learning tool was available in three levels (nursing
students, general nurses and specialist nurses) with positive feedback from users in terms of usefulness,
easiness and intention to use similar online courses.
An exploratory qualitative study of patients’ and healthcare professionals’ views on
self-management in bronchiectasis (C. Kelly, UK)
C. Kelly’s group conducted a study to explore preferences of self-management in adults with
bronchiectasis and healthcare professionals involved in their care. Participants were recruited from three
sites and participated in three focus groups (17 patients) and 11 one-to-one interviews with healthcare
professionals. Findings revealed four themes: 1) what is self-management, 2) the purpose and impact of
self-management, 3) barriers to self-management, and 4) enablers of self-management. The authors of the
study concluded that both groups were positive about self-management, but some barriers were identified.
Specialised healthcare professionals were recognised as precursors to effective self-management.
Patients’ perspectives
Patients’ perspectives on point-of-care diagnostics and treatment by emergency medical
technicians in acute COPD exacerbations: a qualitative study (H.M. Christensen, Denmark)
In Demark, H.M. Christensen’s group explored patients’ perspectives on point-of-care diagnostics and
treatment by emergency medical technicians in acute COPD exacerbations. The group conducted 19
qualitative semistructured interviews which revealed that patients valued the experience and safety of the
ambulance staff using technical equipment and treatment of dyspnoea. Additionally, patients felt confident
when general practitioners followed up the treatment initiated during the emergency episodes at home.
An exploration of dyspnoea and determinants in patients with COPD (E.M. Nerheim, Norway)
E.M. Nerheim’s group examined how physical and affective dimensions of dyspnoea were associated in
203 patients with COPD attending a 4-week inpatient pulmonary rehabilitation programme. According to
the Hospital Anxiety and Depression Scales (HADS), results showed that patients with greater dyspnoea
severity reported a higher degree of anxiety (HADS-A; B: 0.97, p<0.001)) and depression (HADS-D; B:
0.55, p=0.002). The group concluded that an individual approach is needed to explore physical and
affective dimensions of dyspnoea.
Take-home messages
• Respiratory professionals should monitor treatment adherence and reasons for nonadherence in
patients with respiratory conditions.
• Patient engagement and shared decision making between clinicians and patients might be useful to
improve treatment adherence in respiratory care.
• Training and specialised knowledge in respiratory care are important to implement effective
self-management interventions.
• Patients’ perspectives need to be considered during assessment and treatment in respiratory care.
Concluding remarks
This article highlights some of the most memorable sessions during the virtual ERS International
Congress 2020, and provides readers with valuable insight into the latest scientific data and emerging areas
affecting allied respiratory professionals’ clinical practice. The authors wish to inspire readers’ enthusiasm
to appreciate the value of staying up to date in their field of interest. A new scientific group was created
this year in the Allied Health Professionals Assembly, Group 9.04: Psychologists and Behavioural
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Scientists; therefore, we believe that next year there will be even more interesting sessions to share the
latest scientific data. We hope to see you all in Barcelona in 2021 for the next highly successful ERS
International Congress.
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